Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas.

Jenna L Gordon, Kristin J Hinsen, Melissa M Reynolds, Mark A Brown

Open access · goldAbstract read

In one paragraph

Article in Diseases (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.1field-weighted citation impact, top 51% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

Seroprevalence and associated factors ofFrontiers in public health · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jenna L GordonDepartment of Chemistry, Colorado State University, Fort Collins, CO 80521, USA.ORCID 0000-0003-1346-8879

Kristin J HinsenDepartment of Biomedical Sciences, Colorado State University, Fort Collins, CO 80521, USA.

Melissa M ReynoldsDepartment of Chemistry, Department of Chemical and Biological Engineering, School of Biomedical Chemistry, Colorado State University, Fort Collins, CO 80523, USA.

Mark A BrownDepartment of Clinical Sciences, Colorado State University, Fort Collins, CO 80521, USA.

Colorado State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite enormous advances in the detection and treatment of breast cancer, it still remains the leading cancer diagnosis and has the second highest mortality rate. Thus, breast cancer research is a high priority for academics and clinicians alike. Based on previous research indicating the potential of nitric oxide (NO) and SMYD-3 inhibition, this work sought to expand upon these concepts and combine the two approaches. Both NO (from

Indexed as

apoptosisbreast cancercell viabilitycolony formationcytotoxicitynitric oxide

Identifiers

PMID34842655

DOI10.3390/diseases9040082

PMCPMC8628812

OpenAlexW3213588189

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.